Observed Signal · Sep 17, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 1/5 · Sentiment: Positive
MicroLub Raises $10M to Cut Fat Without Compromising Taste
MicroLub, a deep tech ingredient solutions company spun out from the University of Leeds, has raised $10 million in a funding round led by Northern Gritstone, with participation from existing investors including NPIF II - PXN Equity Finance. The company's patented protein-based technology enables food manufacturers to reduce fat and calories by up to 75% while maintaining taste and texture, addressing the reformulation challenges driven by regulation and GLP-1 drug adoption. The funding will support international expansion into the US and Asian markets, team growth, and converting customer trials into commercial agreements.
Funding news for a niche ingredient tech startup, not directly impactful to AdTech; no advertising, marketing, or media relevance.
Track Real-Time Funding Signals & Market Shifts
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- MicroLub raised $10 million in a funding round led by Northern Gritstone.
- All existing investors participated, including NPIF II - PXN Equity Finance.
- The technology can reduce fat and calorie content by up to 75%.
- MicroLub was founded by Professor Anwesha Sarkar from the University of Leeds.
- The funding will support expansion into the US and Asian markets.
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Ferm Labs Raises €3M for Natural Flavor Platform
Ferm Labs, a Swiss-Italian B2B ingredient startup headquartered in Zug, has raised €3 million in a seed round led by CDP Venture Capital's Green Transition Fund, with participation from Fund F, Redstone (with Euregio+ and Alpine VC), and food company Loacker. Founded in 2025 by Stephanie Lüpold and Mattia Baroni, the company uses genetically unmodified microbes to accelerate fermentation from weeks to hours, transforming agricultural side streams into clean-label flavor systems. Its flagship product Kokumesan, upcycled from whey, targets the industrial cheese market in the US and Europe, offering mature cheese flavor while reducing fat, salt, and production costs—claiming 75% cost-in-use savings. The funds will expand bioprocessing facilities in South Tyrol, grow the European B2B sales team, and increase R&D for new product categories, aiming to redefine natural flavors for industrial production.
Musely Gets $360M Non‑Dilutive Funding from General Catalyst
Musely, a direct-to-consumer telemedicine platform specializing in compounded treatments for skin, hair and menopause care, has secured over $360 million in non-dilutive capital from General Catalyst’s Customer Value Fund (CVF). The financing is structured like a revenue-share alternative — not equity and not a traditional interest-bearing loan — allowing Musely to fund sales, marketing and customer-acquisition efforts without diluting ownership. Musely, founded in 2014 and pivoted to prescription skincare in 2019, says it has been cash-flow positive for years, is growing revenue roughly 50% year-over-year, and has served over 1.2 million patients. Musely previously raised $20 million in 2014 and had not taken equity since. CVF’s portfolio includes companies such as Grammarly, Lemonade and Ro.
Biolevate raises €30M Series A for life sciences AI
Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.